Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: TSE:GUD
- CUSIP: N/A
- Web: www.gud-knight.com/
Capitalization:- Market Cap: C$1.23 billion
- Outstanding Shares: 142,765,000
Average Prices:- 50 Day Moving Avg: C$8.63
- 200 Day Moving Avg: C$9.77
- 52 Week Range: C$8.25 - C$11.03
P/E:- Trailing P/E Ratio: 60.07
- P/E Growth: 2880.00
Sales & Book Value:- Annual Revenue: C$7.97 million
- Price / Sales: 154.59
- Book Value: C$6.87 per share
- Price / Book: 1.26
Profitability:- EBIDTA: ($7,640,000.00)
- Net Margins: 18.51%
- Return on Equity: 0.19%
- Return on Assets: 0.19%
Misc:- Average Volume: 169,151 shs.
- Short Ratio: 4.2
Frequently Asked Questions for Knight Therapeutics (TSE:GUD)
What is Knight Therapeutics' stock symbol?
Knight Therapeutics trades on the Tornton Stock Exchange (TSX) under the ticker symbol "GUD."
How were Knight Therapeutics' earnings last quarter?
Knight Therapeutics Inc (TSE:GUD) posted its quarterly earnings data on Thursday, August, 14th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The company earned $0.25 million during the quarter, compared to analyst estimates of $0.13 million. Knight Therapeutics had a return on equity of 0.19% and a net margin of 18.51%. View Knight Therapeutics' Earnings History.
When will Knight Therapeutics make its next earnings announcement?
Where is Knight Therapeutics' stock going? Where will Knight Therapeutics' stock price be in 2017?
4 brokers have issued twelve-month price objectives for Knight Therapeutics' shares. Their predictions range from C$9.80 to C$12.50. On average, they expect Knight Therapeutics' stock price to reach C$10.86 in the next year. View Analyst Ratings for Knight Therapeutics.
Who are some of Knight Therapeutics' key competitors?
Some companies that are related to Knight Therapeutics include Indivior PLC (INDV), Hutchison China MediTech Limited (HCM), Abcam Plc (ABC), Udg Healthcare PLC (UDG), Dechra Pharmaceuticals plc (DPH), Biohaven Pharmaceutical Holding Co Ltd (BHVN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Genus plc (GNS), Clinigen Group PLC (CLIN), ProMetic Life Sciences (PLI), Asante Solutions (PUMP), National HealthCare (NHC), Spire Healthcare Group PLC (SPI), Canfor Pulp Products (CFX), Extendicare (EXE), Novadaq Technologies (NDQ) and CVS Group Plc (CVSG).
How do I buy Knight Therapeutics stock?
Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Knight Therapeutics' stock price today?
One share of Knight Therapeutics stock can currently be purchased for approximately C$8.63.
MarketBeat Community Rating for Knight Therapeutics (TSE GUD)MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Knight Therapeutics (TSE:GUD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | C$10.86 |
Analysts' Ratings History for Knight Therapeutics (TSE:GUD)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 8/11/2017 | National Bank Financial | Lower Price Target | | C$11.75 -> C$10.75 |  |
| 5/12/2017 | Scotiabank | Lower Price Target | Outperform | C$11.00 -> C$10.50 | |
| 3/20/2017 | TD Securities | Reiterated Rating | Buy | C$12.50 | |
| 1/13/2017 | CIBC | Lower Price Target | | C$13.00 -> C$9.80 | |
| 1/4/2017 | Mackie | Downgrade | Buy -> Hold | C$12.00 -> C$10.75 | |
| 11/10/2016 | Bloom Burton | Reiterated Rating | Accumulate | | |
| 3/10/2016 | Paradigm Capital | Set Price Target | Buy | C$9.00 | |
| 3/2/2016 | Dundee Securities | Reiterated Rating | Neutral | | |
(Data available from 9/22/2015 forward)
Earnings History for Knight Therapeutics (TSE:GUD)Earnings History by Quarter for Knight Therapeutics (TSE GUD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2017 | | | | | | | | |
| 8/14/2014 | | C($0.01) | C$0.01 | C$0.13 million | C$0.25 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Knight Therapeutics (TSE:GUD)2017 EPS Consensus Estimate: $0.16
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.04 | $0.07 | $0.06 |
| Q2 2017 | 1 | $0.06 | $0.06 | $0.06 |
| Q3 2017 | 1 | $0.02 | $0.02 | $0.02 |
| Q4 2017 | 1 | $0.02 | $0.02 | $0.02 |
(Data provided by Zacks Investment Research)
Dividend History for Knight Therapeutics (TSE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Knight Therapeutics (TSE:GUD)Insider Trades by Quarter for Knight Therapeutics (TSE:GUD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/24/2015 | Robert Nathaniel Lande | Director | Sell | 57,000 | C$8.85 | C$504,267.60 | |
(Data available from 1/1/2013 forward)
Headline Trends for Knight Therapeutics (TSE:GUD)
Latest Headlines for Knight Therapeutics (TSE:GUD)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Knight Therapeutics, Inc. : August 16, 2017
finance.yahoo.com - August 16 at 7:19 PM |
| Knight Therapeutics, Inc. :GUD-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
finance.yahoo.com - August 15 at 7:54 PM |
 | Knight Therapeutics Inc to Post FY2017 Earnings of $0.15 Per Share, National Bank Financial Forecasts (GUD)
www.americanbankingnews.com - August 14 at 4:44 AM |
| Q3 2017 Earnings Estimate for Knight Therapeutics Inc (TSE:GUD) Issued By Cormark
www.americanbankingnews.com - August 14 at 1:40 AM |
| Knight Therapeutics Inc (TSE:GUD) Price Target Lowered to C$10.75 at National Bank Financial
www.americanbankingnews.com - August 11 at 10:22 PM |
| Knight Reports Second Quarter 2017 Results
finance.yahoo.com - August 11 at 1:26 AM |
| Synergy CHC Corp. Secures up to US$30 Million of Growth Capital
finance.yahoo.com - August 11 at 1:26 AM |
| Edited Transcript of GUD.TO earnings conference call or presentation 10-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 1:26 AM |
| Knight Supports Synergy with Third Secured Loan
finance.yahoo.com - August 9 at 7:28 PM |
| Knight Therapeutics Inc (GUD) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - August 4 at 3:32 PM |
| Notice of Knight Therapeutics' Second Quarter 2017 Results Conference Call
finance.yahoo.com - August 3 at 7:19 PM |
| Knight Therapeutics, Inc. :GUD-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 7:19 PM |
| ETFs with exposure to Knight Therapeutics, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 9:44 PM |
| ETFs with exposure to Knight Therapeutics, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 8:26 PM |
| Knight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : July 7, 2017
finance.yahoo.com - July 8 at 11:16 AM |
| Canadian Healthcare Stocks Under Review: Valeant Pharma International, Knight Therapeutics, Merus Labs International, and Nuvo Pharma
finance.yahoo.com - June 30 at 7:29 PM |
| Knight Therapeutics, Inc. – Value Analysis (TORONTO:GUD) : June 26, 2017
finance.yahoo.com - June 26 at 7:17 PM |
| Knight to Present at the Jefferies Global Healthcare Conference in New York City
finance.yahoo.com - June 2 at 6:54 PM |
| Knight to Present at the National Bank Financial Quebec Conference in Toronto
finance.yahoo.com - May 31 at 8:51 AM |
| Knight Therapeutics Inc to Post FY2017 Earnings of $0.19 Per Share, National Bank Financial Forecasts (GUD)
www.americanbankingnews.com - May 15 at 8:30 AM |
| Q1 2017 EPS Estimates for Knight Therapeutics Inc Increased by Cormark (GUD)
www.americanbankingnews.com - May 15 at 7:00 AM |
| Knight Therapeutics Inc (GUD) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 12 at 9:14 PM |
| Scotiabank Lowers Knight Therapeutics Inc (GUD) Price Target to C$10.50
www.americanbankingnews.com - May 12 at 7:41 PM |
| Analysts Offer Predictions for Knight Therapeutics Inc's Q1 2017 Earnings (GUD)
www.americanbankingnews.com - May 12 at 6:20 PM |
| Knight Therapeutics Inc Expected to Post Q2 2017 Earnings of $0.06 Per Share (GUD)
www.americanbankingnews.com - May 12 at 6:20 PM |
| Knight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : May 12, 2017
finance.yahoo.com - May 12 at 6:14 PM |
 | ‘Purge’ killer given 3 life sentences
www.usatoday.com - May 11 at 11:10 PM |
 | Trump Administration Announces Deal With China to Boost Exports
www.wsj.com - May 11 at 11:10 PM |
 | No charges for white officer in Nashville who shot and killed black man
www.latimes.com - May 11 at 11:10 PM |
 | Hanford Nuclear Site’s Collapsed Tunnel May Have Gone Unnoticed
www.nbcnews.com - May 11 at 11:10 PM |
| Knight Reports First Quarter 2017 Results
finance.yahoo.com - May 11 at 6:09 PM |
| What to Expect for Summer Travel
www.wsj.com - May 10 at 12:20 PM |
| Iraqi boys recount horrors of captivity by IS
www.usatoday.com - May 10 at 12:20 PM |
 | Carney Told to Be Ruthless in Pushing Through BOE Overhaul
www.bloomberg.com - May 10 at 12:20 PM |
| Citigroup Trader Fired Over 5-Word Message Uses 2-Second Defense
www.bloomberg.com - May 10 at 12:20 PM |
 | Donald Trump Says He Fired FBI Director Because He Wasn't 'Doing A Good Job'
www.huffingtonpost.com - May 10 at 12:20 PM |
| Knight Therapeutics Inc. announces voting results from the Annual Meeting
finance.yahoo.com - May 10 at 12:20 PM |
 | 82nd Airborne already on way to Afghanistan as Trump mulls more deployments
www.foxnews.com - May 9 at 5:23 PM |
| White House Skeptical of Yates’ Heads Up on Flynn, Cited Partisan Motives
www.nbcnews.com - May 9 at 5:23 PM |
| GOP senators can cut Obamacare taxes or preserve coverage for millions — but probably not both
www.latimes.com - May 9 at 5:23 PM |
| Audio Reveals Final Pleas Of Hundreds Of Refugees Trapped On A Sinking Boat
www.huffingtonpost.com - May 9 at 12:43 PM |
 | Meghan Markle, Prince Harry show PDA at polo match for first time
abcnews.go.com - May 8 at 8:20 AM |
| 2 doctors found dead in Boston penthouse probably knew their killer, police say
www.latimes.com - May 7 at 10:49 PM |
| What's at stake as Trump gets to 'see you in court' in two major travel ban cases
www.latimes.com - May 7 at 10:49 PM |
| Ali Lowitzer’s Mother Pushes for Day Daughter Disappeared to Become Texas Missing Persons Day
www.nbcnews.com - May 7 at 10:49 PM |
| Texas governor signs bill targeting sanctuary cities
www.foxnews.com - May 7 at 10:49 PM |
| Nicki Minaj Offers to Pay Over a Dozen Fans’ Student Loans on Twitter
www.nbcnews.com - May 7 at 5:49 PM |
| North Korea Detains Fourth American Citizen: KCNA Report
www.nbcnews.com - May 7 at 10:01 AM |
| Aunt Jemima Products Recalled Due to Possible Listeria Contamination
www.nbcnews.com - May 6 at 5:40 PM |
| Obama White House counsel part of early talks on Clinton email release, notes show
www.foxnews.com - May 5 at 9:11 PM |
Knight Therapeutics (GUD) Chart for Friday, September, 22, 2017
